Payment overview · 2025
General Payments
$503.91
25 reported records · 14 companies
Healthcare provider profile · identity verified
Thomas Paul Evans, MD
Allopathic & Osteopathic Physicians|Internal Medicine · HUNTINGDON, TN · NPI 1841285228
Verified facts
What the public records show
CMS Open Payments records show Thomas Paul Evans, MD received $503.91 in general payments during 2025 across 25 reported records.
PFIZER INC. accounted for 22.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 162 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $111.17 | 22.1% | 5 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $95.71 | 19.0% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $65.24 | 12.9% | 4 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $32.95 | 6.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $28.73 | 5.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $27.06 | 5.4% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $21.51 | 4.3% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $20.31 | 4.0% | 1 | 2025 |
| CorVista Health, Inc. | Unresolved — no canonical attribution shown | $20.00 | 4.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $19.02 | 3.8% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.09 | 3.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.71 | 3.1% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.58 | 2.9% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $13.83 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $503.91 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $95.71 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $90.33 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $90.33 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $46.48 | 3 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $32.95 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $28.73 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $28.73 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $27.06 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $27.06 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $21.51 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $20.84 | 1 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $20.84 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $20.84 | 1 | 2025 |
Source payment records
|
|||||
| TRUMENBA Normalized: trumenba |
Biological | PFIZER INC. | $20.84 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $20.31 | 1 | 2025 |
Source payment records
|
|||||
| CorVista System Normalized: corvista system |
Device | CorVista Health, Inc. | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.02 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.02 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.76 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $18.09 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.71 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.71 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $14.58 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $14.58 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $13.83 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 54 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 132 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
64 | 22 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
54 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
72 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
132 | 24 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
162 | 30 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 437 | 138 |
| Levothyroxine Sodium | Levothyroxine Sodium | 333 | 77 |
| Omeprazole | Omeprazole | 310 | 76 |
| Furosemide | Furosemide | 304 | 88 |
| Amlodipine Besylate | Amlodipine Besylate | 295 | 100 |
| Pantoprazole Sodium | Pantoprazole Sodium | 289 | 79 |
| Gabapentin | Gabapentin | 253 | 90 |
| Lisinopril | Lisinopril | 242 | 84 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 221 | 83 |
| Metformin Hcl | Metformin Hcl | 190 | 59 |
| Metoprolol Tartrate | Metoprolol Tartrate | 186 | 47 |
| Simvastatin | Simvastatin | 185 | 52 |
| Meloxicam | Meloxicam | 176 | 44 |
| Escitalopram Oxalate | Escitalopram Oxalate | 169 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 166 | 45 |
| Losartan Potassium | Losartan Potassium | 164 | 50 |
| Eliquis | Apixaban | 162 | 30 |
| Carvedilol | Carvedilol | 161 | 42 |
| Potassium Chloride | Potassium Chloride | 161 | 51 |
| Trazodone Hcl | Trazodone Hcl | 150 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 143 | 41 |
| Allopurinol | Allopurinol | 139 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 136 | 39 |
| Alprazolam | Alprazolam | 133 | 35 |
| Ozempic | Semaglutide | 132 | 24 |
| Tramadol Hcl | Tramadol Hcl | 125 | 56 |
| Duloxetine Hcl | Duloxetine Hcl | 120 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 108 | 35 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 107 | 36 |
| Entresto | Sacubitril/Valsartan | 104 | 17 |
| Famotidine | Famotidine | 102 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 102 | 46 |
| Pregabalin | Pregabalin | 94 | 24 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 91 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 89 | 26 |
| Lovastatin | Lovastatin | 86 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 85 | 30 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 81 | 22 |
| Sertraline Hcl | Sertraline Hcl | 80 | 29 |
| Clonazepam | Clonazepam | 72 | 25 |
| Jardiance | Empagliflozin | 72 | 19 |
| Warfarin Sodium | Warfarin Sodium | 70 | 17 |
| Linzess | Linaclotide | 64 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 62 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 61 | 11 |
| Montelukast Sodium | Montelukast Sodium | 60 | 23 |
| Spironolactone | Spironolactone | 60 | 19 |
| Donepezil Hcl | Donepezil Hcl | 59 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 58 | 29 |
| Tresiba Flextouch U-100 | Insulin Degludec | 58 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 57 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 56 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 56 | 23 |
| Lamotrigine | Lamotrigine | 56 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 55 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 54 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 54 | 19 |
| Ezetimibe | Ezetimibe | 51 | 16 |
| Lorazepam | Lorazepam | 51 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 50 | suppressed |
| Fenofibrate | Fenofibrate | 50 | suppressed |
| Repatha Sureclick | Evolocumab | 49 | suppressed |
| Levetiracetam | Levetiracetam | 48 | 16 |
| Diazepam | Diazepam | 47 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 47 | 13 |
| Methylprednisolone | Methylprednisolone | 47 | 47 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 46 | 16 |
| Buspirone Hcl | Buspirone Hcl | 44 | suppressed |
| Temazepam | Temazepam | 44 | suppressed |
| Cephalexin | Cephalexin | 43 | 39 |
| Pravastatin Sodium | Pravastatin Sodium | 43 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 41 | 38 |
| Celecoxib | Celecoxib | 41 | 11 |
| Clonidine Hcl | Clonidine Hcl | 41 | suppressed |
| Glimepiride | Glimepiride | 41 | 13 |
| Mirtazapine | Mirtazapine | 40 | 13 |
| Prednisone | Prednisone | 40 | 28 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 40 | 17 |
| Synthroid | Levothyroxine Sodium | 39 | suppressed |
| Atenolol | Atenolol | 38 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 37 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 37 | suppressed |
| Tradjenta | Linagliptin | 37 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 36 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 36 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 35 | 25 |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 33 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 33 | suppressed |
| Baclofen | Baclofen | 33 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 33 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 32 | 17 |
| Primidone | Primidone | 32 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 32 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 32 | suppressed |
| Memantine Hcl | Memantine Hcl | 31 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 27 |
| Dicyclomine Hcl | Dicyclomine Hcl | 30 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | suppressed |
| Ondansetron Odt | Ondansetron | 30 | 26 |
| Rybelsus | Semaglutide | 30 | suppressed |
| Methocarbamol | Methocarbamol | 29 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 28 | suppressed |
| Januvia | Sitagliptin Phosphate | 28 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Azithromycin | Azithromycin | 25 | 23 |
| Benztropine Mesylate | Benztropine Mesylate | 25 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 25 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Haloperidol | Haloperidol | 25 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 25 | suppressed |
| Torsemide | Torsemide | 25 | suppressed |
| Finasteride | Finasteride | 24 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 22 | 22 |
| Carisoprodol | Carisoprodol | 22 | suppressed |
| Dutasteride | Dutasteride | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 22 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 22 | suppressed |
| Carbamazepine | Carbamazepine | 21 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 17 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 21 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 21 | suppressed |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Nystatin | Nystatin | 20 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 20 | suppressed |
| Vraylar | Cariprazine Hcl | 20 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 19 | suppressed |
| Febuxostat | Febuxostat | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 19 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Methotrexate | Methotrexate Sodium | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | 11 |
| Oxcarbazepine | Oxcarbazepine | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Xifaxan | Rifaximin | 16 | suppressed |
| Brilinta | Ticagrelor | 15 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 15 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Naproxen | Naproxen | 15 | 13 |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 14 |
| Clindamycin Hcl | Clindamycin Hcl | 14 | 12 |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Galantamine Er | Galantamine Hbr | 14 | suppressed |
| Lubiprostone | Lubiprostone | 14 | suppressed |
| Prolia | Denosumab | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | 13 |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Humira Pen | Adalimumab | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 11 |
| Lithium Carbonate | Lithium Carbonate | 13 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $503.91 · 25 records | PFIZER INC. | AIRSUPRA, Auvelity, CAPLYTA, COMIRNATY, CorVista System, ENFLONSIA, FARXIGA, GARDASIL 9, INGREZZA, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PENBRAYA, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, SKYCLARYS, TRUMENBA, The Cologuard Plus Collection Kit, UBRELVY, ZAVZPRET, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error